[The level of erythropoietin in patients with anemia and myeloma multiplex treated with erythropoietin].
6 patients with anaemia associated with myeloma multiplex were treated with human recombinant erythropoietin (rHuEPO, Exprex*) at a dose of 150 units/kg s.c. three times a week for 12 weeks. A good response, defined as an increase of hemoglobin > 20 milligrams above the pretreatment level, was achieved in 4 patients. The erythropoietin serum concentration was measured four times in each patient: twice before commencing and twice after completing the treatment. In patients who responded to rHuEPO therapy the Epo serum concentration decreased whereas in non-responders increased.
Ciepłuch
H
H
Kliniki Hematologii, Instytutu Chorób Wewnetrznych Akademii Medycznej w Gdańsku.
Zaucha
J M
JM
Lysiak-Szydłowska
W
W
Hellmann
A
A
D000368:Aged; D000740:Anemia / Q000097:blood / Q000628:therapy*; D004921:Erythropoietin / Q000097:blood* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin